WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
The house we're buying has been downvalued by £40k: What should we do?Winner of North Macedonia's parliamentary election to seek governing coalition partnerRise of the childless couple: OppositeIntruder tries to break into Drake's house one day after his security guard was shot outsideSpanish court shelves latest tax probe of Shakira following prosecutors' recommendationPolice cordon off semiHero father who 'protected his wife and daughter from swordCan YOU afford to become a stayThe house we're buying has been downvalued by £40k: What should we do?Tory exodus gathers pace as ex
2.8982s , 6500.6328125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,World Winds news portal